Log in

NYSE:MNKMallinckrodt Stock Price, Forecast & News

$3.37
-0.01 (-0.30 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.30
Now: $3.37
$3.55
50-Day Range
$1.70
MA: $3.15
$3.93
52-Week Range
$1.00
Now: $3.37
$10.54
Volume2.75 million shs
Average Volume5.43 million shs
Market Capitalization$284.63 million
P/E RatioN/A
Dividend YieldN/A
Beta3.57
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company was founded in 1867 and is based in Staines-Upon-Thames, the United Kingdom.
Read More
Mallinckrodt logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-0-17-8463-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.16 billion
Cash Flow$19.82 per share
Book Value$23.08 per share

Profitability

Net Income$-996,500,000.00

Miscellaneous

Employees3,400
Market Cap$284.63 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.

Mallinckrodt (NYSE:MNK) Frequently Asked Questions

How has Mallinckrodt's stock been impacted by COVID-19 (Coronavirus)?

Mallinckrodt's stock was trading at $3.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MNK stock has increased by 10.5% and is now trading at $3.37. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Mallinckrodt?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 3 sell ratings, 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Mallinckrodt.

When is Mallinckrodt's next earnings date?

Mallinckrodt is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Mallinckrodt.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) posted its quarterly earnings results on Tuesday, May, 5th. The company reported $1.64 earnings per share for the quarter, topping the consensus estimate of $1.43 by $0.21. The company earned $665.80 million during the quarter, compared to analyst estimates of $687.07 million. Mallinckrodt had a negative net margin of 39.56% and a positive return on equity of 29.14%. Mallinckrodt's quarterly revenue was down 15.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.94 EPS. View Mallinckrodt's earnings history.

What price target have analysts set for MNK?

16 Wall Street analysts have issued 1-year price objectives for Mallinckrodt's shares. Their forecasts range from $2.00 to $22.00. On average, they anticipate Mallinckrodt's share price to reach $7.93 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price. View analysts' price targets for Mallinckrodt.

Has Mallinckrodt been receiving favorable news coverage?

News stories about MNK stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mallinckrodt earned a news impact score of 1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutMallinckrodt.

Are investors shorting Mallinckrodt?

Mallinckrodt saw a decline in short interest in May. As of May 15th, there was short interest totaling 52,080,000 shares, a decline of 5.1% from the April 30th total of 54,860,000 shares. Based on an average daily volume of 8,170,000 shares, the days-to-cover ratio is currently 6.4 days. Approximately 62.6% of the company's stock are short sold. View Mallinckrodt's Current Options Chain.

Who are some of Mallinckrodt's key competitors?

What other stocks do shareholders of Mallinckrodt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Endo International (ENDP), Gerdau (GGB), Celgene (CELG), Alibaba Group (BABA), Skyworks Solutions (SWKS) and AT&T (T).

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the following people:
  • Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 58)
  • Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 50)
  • Mr. Matthew K. Harbaugh, Exec. VP & Pres of Specialty Generics (Age 49)
  • Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 56)
  • Mr. Bryan M. Reasons, Chief Financial Officer (Age 52)

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

Who are Mallinckrodt's major shareholders?

Mallinckrodt's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.58%), Morgan Stanley (3.81%), State Street Corp (2.92%), Creative Planning (2.36%), Parametric Portfolio Associates LLC (2.16%) and Deutsche Bank AG (1.78%). Company insiders that own Mallinckrodt stock include Bryan M Reasons and Mark Trudeau. View institutional ownership trends for Mallinckrodt.

Which institutional investors are selling Mallinckrodt stock?

MNK stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Two Sigma Investments LP, JPMorgan Chase & Co., Morgan Stanley, Nuveen Asset Management LLC, Ikarian Capital LLC, Tudor Investment Corp Et Al, and Two Sigma Advisers LP. View insider buying and selling activity for Mallinckrodt.

Which institutional investors are buying Mallinckrodt stock?

MNK stock was bought by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Centerbridge Partners L.P., Creative Planning, State Street Corp, Paloma Partners Management Co, Parametric Portfolio Associates LLC, BlackRock Inc., and APG Asset Management N.V.. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons, and Mark Trudeau. View insider buying and selling activity for Mallinckrodt.

How do I buy shares of Mallinckrodt?

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $3.37.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $284.63 million and generates $3.16 billion in revenue each year. The company earns $-996,500,000.00 in net income (profit) each year or $8.88 on an earnings per share basis. Mallinckrodt employs 3,400 workers across the globe.

What is Mallinckrodt's official website?

The official website for Mallinckrodt is www.mallinckrodt.com.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.